133 related articles for article (PubMed ID: 20863430)
1. Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders.
Islam MS; Anoop P; Gordon-Smith EC; Rice P; Datta-Nemdharry P; Marsh JC
Hematology; 2010 Oct; 15(5):344-50. PubMed ID: 20863430
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
3. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
[TBL] [Abstract][Full Text] [Related]
7. Early cytomegalovirus infections following allogeneic stem cell transplantation: a comparison between non-malignant and malignant haematological disorders.
Islam MS; Anoop P; Rice P; Benjamin R; Datta-Nemdharry P; Gordon-Smith EC; Marsh JC
Hematology; 2010 Feb; 15(1):4-10. PubMed ID: 20132656
[TBL] [Abstract][Full Text] [Related]
8. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
[TBL] [Abstract][Full Text] [Related]
9. Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival.
Auger S; Orsini M; Céballos P; Fegueux N; Kanouni T; Caumes B; Klein B; Villalba M; Rossi JF
Eur J Haematol; 2014; 92(5):421-8. PubMed ID: 24400833
[TBL] [Abstract][Full Text] [Related]
10. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
Xuan L; Huang F; Fan Z; Zhou H; Zhang X; Yu G; Zhang Y; Liu C; Sun J; Liu Q
J Hematol Oncol; 2012 Aug; 5():46. PubMed ID: 22856463
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases.
Nash RA; Dansey R; Storek J; Georges GE; Bowen JD; Holmberg LA; Kraft GH; Mayes MD; McDonagh KT; Chen CS; Dipersio J; Lemaistre CF; Pavletic S; Sullivan KM; Sunderhaus J; Furst DE; McSweeney PA
Biol Blood Marrow Transplant; 2003 Sep; 9(9):583-91. PubMed ID: 14506660
[TBL] [Abstract][Full Text] [Related]
12. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
13. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
Lindsay J; Othman J; Yong MK; Ritchie D; Chee L; Tay K; Tio SY; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Greenwood M; Pergam SA; Liu C; Slavin MA
Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.
Liu QF; Ling YW; Fan ZP; Jiang QL; Sun J; Wu XL; Zhao J; Wei Q; Zhang Y; Yu GP; Wu MQ; Feng R
Transpl Infect Dis; 2013 Aug; 15(4):379-92. PubMed ID: 23692640
[TBL] [Abstract][Full Text] [Related]
16. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
17. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
[TBL] [Abstract][Full Text] [Related]
18. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.
Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
Oncotarget; 2016 May; 7(21):30230-40. PubMed ID: 27102298
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
20. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia.
Buyck HC; Ball S; Junagade P; Marsh J; Chakrabarti S
Bone Marrow Transplant; 2009 May; 43(10):813-6. PubMed ID: 19104495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
